Dr. Stephen Freedman Joins Ingenium as Executive Vice President, Corporate Development
Ingenium Pharmaceuticals AG announced that Stephen Freedman, Ph.D., has joined the company as Executive Vice President, Corporate Development. Dr. Freedman's responsibilities will include the strategic development of Ingenium's growing pipeline of pain and chronic inflammatory disease drug candidates and the expansion of Ingenium's presence in the United States.
Prior to joining the company, Dr. Freedman supported Ingenium in the capacity of an expert in drug discovery and development. Dr. Freedman's pharmaceutical industry experience includes more than 10 years at Elan Pharmaceuticals, his last position being Senior Vice President, Head of Global Research at Elan's San Francisco site. Prior to Elan, Dr. Freedman spent over 12 years at Merck & Co., Inc. He received his Ph.D. in Pharmacology from the University of Southampton, England.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.